Telehealth Companies Expand GLP-1 Access Amid Safety and Screening Concerns
Telehealth platforms have rapidly scaled access to GLP-1 weight loss medications in response to surging patient demand. Researchers and physicians have raised concerns that some online providers may not adequately screen patients for contraindications or provide appropriate clinical monitoring during treatment. The safety questions emerge as telehealth prescribing of these high-cost medications expands outside traditional clinical settings. The controversy affects how managed care organizations evaluate telehealth vendor networks and pharmacy benefit management for GLP-1 drugs.
Managed care organizations must evaluate telehealth vendor credentialing standards and clinical protocols for high-cost GLP-1 prescribing, as inadequate screening could drive adverse events, prior authorization disputes, and pharmacy cost increases.
Pharmacy · Managed Care
You might also like